Case Study: how reports of falsified medicinal products can impact wholesale distributors
|
|
- Ashlynn Blake
- 6 years ago
- Views:
Transcription
1 Case Study: how reports of falsified medicinal products can impact wholesale distributors Amy Kelly Ph.D. Wholesale Distribution Conference 11 th November 2014
2 Overview Legal basis Falsified medicine issues as quality defects Overview of recent falsified medicines issues affecting Member States HPRA communications to wholesalers and requests for checks and actions Wholesaler controls to prevent receipt of falsified product 11th November
3 Falsified medicinal product - definition Any medicinal product with a false representation of: (a) its identity, including its packaging and labelling, its name or its composition as regards any of the ingredients including excipients and the strength of those ingredients; (b) its source, including its manufacturer, its country of manufacturing, its country of origin or its marketing authorisation holder; or (c) its history, including the records and documents relating to the distribution channels used. Directive 2011/62/EU, Directive 2001/83/EC Guidelines of 5 November 2013 on Good Distribution Practice of Medicinal Products for Human Use (2013/343/01) 11th November
4 Medicinal Products (Control of Placing on the Market) Regulations 2007, as amended (SI 162 of 2013) PART 8: Prohibitions in relation to falsified medicinal products A person shall not a) place a medicinal product on the market b) place a medicinal product into circulation c) introduce a medicinal product into the State, or d) sell or supply, or offer for sale or supply a medicinal product, including from a distance by means of information society services, if he or she knows, or there are sufficient grounds to suspect, that it is a falsified medicinal product 11th November
5 Medicinal Products (Control of Placing on the Market) Regulations 2007, as amended (SI 162 of 2013) PART 9: System to prevent medicinal products, suspected of presenting a danger to health, reaching patients requires HPRA to operate a system which provides for: a) the receipt and handling of notifications of suspected falsified medicinal products and suspected quality defects of medicinal products, b) the recall of a medicinal product by holders of a Community marketing authorisations, marketing authorisations, certificates of registration or certificates of traditional-use registration c) the withdrawal from the market of medicinal products from all relevant actors in the supply chain both during and outside normal working hours, d) the recall from the market, where necessary with the assistance of health professionals, of medicinal products from patients who have received such products. 11th November
6 Medicinal Products (Control of Placing on the Market) Regulations 2007, as amended (SI 162 of 2013) SI 162 of 2013 Part 9 requires the HPRA, where it identifies a medicinal product which is suspected of presenting a serious risk to public health, to, where necessary and without delay, rapidly transmit a notification to all EEA States and all actors in the supply chain who are located in the State and who may hold stocks of the relevant medicinal product 11th November
7 Falsified Medicines Issues as Quality Defects Falsified medicines issues are investigated by HPRA as Quality Defect cases (QDRs) by Market Compliance We work closely on these issues with colleagues including: HPD Enforcement Pharmacovigilance Other Competent Authorities 11th November
8 Falsified Medicines Issues as Quality Defects All falsified medicines cases are treated as critical, high-risk, quality defects, i.e. highest priority Falsified medicines issues typically notified to HPRA by other Agency or by MAH for genuine product A number of falsified medicines cases are investigated annually as QDRs, e.g. 5 in th November
9 Falsified Medicines Issues in 2014 Case 1 April 2014: Confirmed falsified product, labelled originally as Herceptin 150mg Powder for Concentrate for Solution for Infusion identified in three European markets (UK, Germany and Finland) The packs featured genuine batch numbers and were in Italian livery The units had been stolen from an Italian hospital and re-introduced to the legitimate supply chain 11th November
10 Actions requested by HPRA communication from HPRA to RPs outlining the issue and requesting RPs to indicate if the impacted batches had ever been received into their wholesale facility advising vigilance when ordering and receiving the concerned product in the future 11th November
11 Falsified Medicines Issues in 2014 Case 1 May 2014: HPRA received further information that unauthorised wholesalers were channelling falsified product into the legitimate supply chain via authorised Italian wholesalers Affected products deemed falsified as the supply chain could not be verified 11th November
12 Falsified Medicines Issues in 2014 Case 1 May 2014 Complete listing of affected products unavailable Listings provided by Italian colleagues of 1. Unauthorised wholesalers in several MS (Cyprus, Hungary, Latvia, Romania, Slovak Republic and Slovenia) who supplied falsified product to 2. Authorised Italian wholesalers 11th November
13 Requested actions communication from HPRA to Stakeholders Providing two lists: 1. Unauthorised wholesalers 2. Authorised Italian wholesalers Requesting check of list of suppliers and related records for preceding 5 years to determine if any medicinal product received from these operators Requesting immediate quarantine of any stock from the unauthorised wholesalers If units identified, to contact HPRA immediately 11th November
14 Falsified Medicines Issues in 2014 Case 1 Further updates in 1. July 2014: To identify an additional unauthorised wholesaler, in Romania, and an additional authorised wholesaler, in Malta, impacted by the issue 2. Aug 2014: To identify an additional unauthorised wholesaler, in Greece 11th November
15 Requested actions As before, from HPRA to Stakeholders Providing updated listings Requesting check of list of suppliers and related records for the last 5 years to determine if any medicinal product received from any of the listed wholesalers Requesting immediate quarantine of any stock from the unauthorised wholesalers If units identified, to contact HPRA immediately 11th November
16 Falsified Medicines Issues in 2014 Case 2 Separate communication from Romanian colleagues regarding identification of illegal supply by an authorised wholesaler The authorised wholesaler acquired products from pharmacies, i.e. not an authorised supply chain, and distributed these onwards Connection between this issue and latter issue not confirmed at this time 11th November
17 Requested actions communication from HPRA to Stakeholders Outlining the issue Requesting a check of list of suppliers and related records for the last 5 years to determine if any medicinal product received from this wholesaler If supplies identified, to contact HPRA immediately 11th November
18 Falsified Medicines Issues in 2014 Expect further correspondence of this nature from HPRA Be prepared to check approved supplier lists and other related records Exercise vigilance 11th November
19 Controls that should be in place to prevent receipt of falsified products Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 343/01) HPRA Guide to Good Distribution Practice of Medicinal Products for Human Use (IA-G0046-2) 11th November
20 Chapter 5 OPERATIONS EU GDP Guidelines C Principle All actions taken by wholesale distributors should ensure that the identity of the medicinal product is not lost and that the wholesale distribution of medicinal products is performed according to the information on the outer packaging 11th November
21 Chapter 5 OPERATIONS HPRA Guide to GDP IA-G Supplier approval Prior to purchase and receipt of any medicinal product, wholesalers must verify compliance of the supplying wholesale distributor or manufacturer with GDP e.g. verifying WDA and current GDP Cert The wholesaler is responsible for establishing the authority of the supplier to supply medicinal products and for obtaining appropriate documentary evidence Periodic checks on existing suppliers should be performed to ensure that they maintain an authorised status and that any changes in sourcing arrangements are evaluated 11th November
22 Approving suppliers 5.10 Supplier approval/new suppliers A robust system for approval of new medicinal product suppliers is a key component in the prevention of falsified medicines entering the supply chain In addition to establishing the authority of the supplier, wholesalers should reasonably assure themselves that previous stages in the supply chain are considered to be sufficiently robust to ensure the legitimacy of the medicinal products concerned The RP should be involved in the approval of new suppliers 11th November
23 Approving suppliers 5.10 Supplier approval The system of supplier approval should be described in a procedure and all relevant steps documented Wholesalers are requested to report to the HPRA any issues they consider suspicious or unusual with respect to sourcing of medicinal products 11th November
24 Chapter 5 OPERATIONS 5.23 Falsified medicinal products Wholesalers must: Have an SOP detailing processes to be followed in event of suspected falsified medicines Ensure that the goods-in SOP involves a detailed inspection of products received which is capable of identifying changes or unusual appearance indicative of falsified units Train staff to be aware of falsified products and what to look out for 11th November
25 5.23 Falsified medicinal products Wholesalers must: Maintain a list of approved suppliers and ensure that products are only sourced directly from these Have robust systems for ensuring legitimacy of suppliers and ensure that this is regularly reviewed Be familiar with the history of the supply chain 11th November
26 5.23 Falsified medicinal products Wholesalers must Be aware of possibility of falsified product entering the supply chain through legitimate sources, i.e. other authorised wholesalers or returns Never allow their WDA to be used by third parties to source or supply product Be suspicious of low-cost offers and be familiar with normal/expected market price 11th November
27 5.23 Falsified medicinal products A wholesaler in possession of a product that is found to be (or suspected of being) falsified is responsible for removal and quarantine of the product from saleable stock. The MAH and HPRA should be informed immediately of any suspected falsified product Suspected falsified product should never be returned to the supplier without the consent of HPRA Any suspicious approaches or activities noticed by a wholesaler should be notified to HPRA without delay 11th November
28 Summary Falsified medicine issues as quality defects Overview of recent falsified medicines issues affecting Member States HPRA communications to wholesalers and requests for checks and actions Wholesaler controls to prevent receipt of falsified product 11th November
29 Contacting Quality Defects and Recalls Breda Gleeson (Market Compliance Inspector) Rob Smyth (Market Compliance Technical Officer) Amy Kelly (Quality Defects & Recall Manager) Kevin O Donnell (Market Compliance Manager) Louise Bright (Market Compliance Administrator) 11th November
30 Thank you 11th November
Session 4: Quality Defect Investigations and Product Recalls
Session 4: Quality Defect Investigations and Product Recalls Amy Kelly Ph.D. and Kevin O Donnell Ph.D. GMP Conference 12 th November 2014 Outline The application of QRM principles to QD investigations
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationWholesaling & Distribution & the GMPs
Wholesaling & Distribution & the GMPs Presented by Bryan Wright 11 th July 2016 Overview Wholesaling & distribution of Medicines (FPs) in the EU New EU GDP Guidelines Expectations How complicated can the
More informationGuide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland
Guide to Wholesaling and Brokering of Medicinal Products for Human Use in Ireland IA-G0008-5 17 JUNE 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance
More informationNew GDP Guidelines - Implementation
New GDP Guidelines - Implementation Alfred Hunt, Inspector Wholesale Distribution Conference 11 th November 2014 New GDP Guidelines 2013/C 63/01-8 th September 2013 2013/C 343/01-5 th November 2013 2 1994
More informationFeedback from Inspection Programme
Feedback from Inspection Programme Wholesale Distribution Conference 8 th February 2017 Darren Scully Health Products Distribution Manager Wholesale distribution overview wholesale distribution procure
More informationdistributors with FMD & DR
Challenges for wholesale distributors with FMD & DR implementation on national level Monika Derecque-Pois Director General, GIRP (European Healthcare Distribution Association) 9 November 2017 Who needs
More informationBackground to the Falsified Medicines Directive and the Delegated Regulation. Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016
Background to the Falsified Medicines Directive and the Delegated Regulation Susan Grieve, Principal Pharmacist, Department of Health 12 April 2016 Background to the Falsified Medicines Directive and the
More informationGuide to Quality Defect Investigation Reports
Guide to Quality Defect Investigation Reports SUR-G0020-2 22 NOVEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. 1 SCOPE This
More informationMHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents
MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Enforcement activities - Impact of the falsified medicines directive Presented by: Peter Blundell, GDP Inspector Impact of the falsified
More informationMaterials Management Traceability, CEPs and managing non-conforming sites
Materials Management Traceability, CEPs and managing non-conforming sites IMB Information Day, 14 th October 2010 Dr Cormac Dalton Inspector 13-Oct-10 Slide 1 Managing Supply Supply Demand Supply chain
More informationGuide to Scientific and Regulatory Advice for GXP activities
Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationMA Compliance Reviews Implications for Manufacturers
MA Compliance Reviews Implications for Manufacturers Breda Gleeson, Market Compliance Inspector GMP Conference 12 th November 2014 Scope Role of the Manufacturer in MA Compliance MA Compliance Reviews
More informationMEDICINES CONTROL COUNCIL
Licence to act as a Wholesaler or Distributor MEDICINES CONTROL COUNCIL GUIDELINES FOR LICENCE TO ACT AS A WHOLESALER or DISTRIBUTOR This guideline is intended to provide recommendations to applicants
More informationGuide to Quality System for General Sale Wholesale Distributors
Guide to Quality System for General Sale Wholesale Distributors IA-G0038-5 20 DECEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationGuide to Good Distribution Practice of Medicinal Products for Human Use
Guide to Good Distribution Practice of Medicinal Products for Human Use IA-G0046-3 9 NOVEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
More informationPractical implementation of the Falsified Medicines Directive
Practical implementation of the Falsified Medicines Directive Belén Escribano Romero Head of Pharmaceutical Inspection and Enforcement Department AEMPS 1 Content Development of the Directive Overview of
More informationRegulating risks of falsified medicinal products in the legal distribution chain Safety features - Legal and Regulatory issues
Regulating risks of falsified medicinal products in the legal distribution chain Safety features - Legal and Regulatory issues Annika Wennberg, Medical Products Agency New definition Falsified human medicinal
More informationMaritime and Coastguard Agency LogMARINE GUIDANCE NOTE
Maritime and Coastguard Agency LogMARINE GUIDANCE NOTE MGN 524 (M+F) Life-Saving Appliances - Category C Medical Kits - Wholesale Distribution Authorisation - Wholesale Dealers Licence Notice to all :-
More informationGuide to Parallel Imports of Human Medicines
Guide to Parallel Imports of Human Medicines Deleted: MAY 2016 AUT-G0006-13 04 FEBRUARY 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More information(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
21.3.2015 EN Official Journal of the European Union C 95/1 II (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION Guidelines of 19 March 2015 on
More informationPrimary Distribution Activities
Primary Distribution Activities Wholesale Distribution Information Day, Paul Sexton GMP Manager Date Insert on Master Slide Slide 1 Topics What is a Primary Distributor / Wholesaler Special Responsibilities
More informationReview of HPRA Draft Guide to Distribution of Medical Devices, including in vitro diagnostic Medical Devices
Review of HPRA Draft Guide to Distribution of Medical Devices, including in vitro diagnostic Medical Devices Ref: IA-G0004-x Summary DCC Vital welcomes the new draft guidance which will provide clarity
More informationIMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU. IPA/EDQM/WHO 2012, Mumbai
IMPLEMENTATION OF THE EU FALSIFIED MEDICINES DIRECTIVE, 2011/62/EU from the perspective of Indian manufacturers and Indian authorities IPA/EDQM/WHO 2012, Mumbai S.M.MUDDA Micro Labs Limited, Bangalore
More informationTimeline for the Drug Supply Chain and Security Act
April 2014 Timeline for the Drug Supply Chain and Security Act (Title II, Drug Quality and Security Act, 2013) Overview The Drug Supply Chain and Security Act (Title II, Drug Quality and Security Act,
More informationEMVO FMD Workshop Brussels 13. December 2016
EMVO FMD Workshop Brussels 13. December 2016 Supervision by National Competent Authorities and Access to Data Andreas Walter & Paul Mills dd/mm/yyyy FMD & DR objectives (1) FMD - purpose of the SF Art.
More informationGUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL PRODUCTS FOR HUMAN USE
PHARMACEUTICAL INSPECTION CONVENTION PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PI 047-1 Annex 1 July 2018 GUIDELINES ON THE PRINCIPLES OF GOOD DISTRIBUTION PRACTICE OF ACTIVE SUBSTANCES FOR MEDICINAL
More informationDealing with Quality Defects and Rapid Alerts. David Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency
Dealing with Quality Defects and Rapid Alerts David Cockburn Head of Manufacturing and Quality Compliance European Medicines Agency Contents Responsibilities Procedures for quality defects Related procedures
More informationANNEXES. to the proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
EUROPEAN COMMISSION Brussels, 12.9.2018 COM(2018) 631 final ANNEXES 1 to 6 ANNEXES to the proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on the European Border and Coast Guard
More informationAn analysis of quality product defects in the centralised procedure
European Medicines Agency Inspections London, 18 January 2007 Doc. Ref. EMEA/INS/GMP/23020/2007 An analysis of quality product defects in the centralised procedure 1. Executive Summary An analysis is presented
More informationEarlsfort Centre Earlsfort Terrace Dublin 2 Ireland
Earlsfort Centre Earlsfort Terrace Dublin 2 Ireland GUIDANCE NOTE ON THE WHOLESALING OF MEDICINAL PRODUCTS FOR HUMAN USE IN IRELAND OCTOBER 2004 This guidance note does not purport to be the definitive
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY. EudraLex. Volume 4
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Ref. Ares(2015)4234460-12/10/2015 Medicinal products quality, safety and efficacy Brussels, 12 October 2015 EudraLex Volume 4 EU Guidelines
More informationOverview of HPRA Sampling and Analysis (S&A) Programme
Overview of HPRA Sampling and Analysis (S&A) Programme Considerations for Wholesalers Patrick Saunders & Kevin O Donnell Wholesale Distribution Conference 11 th November 2014 Objective & Scope This is
More informationGuidelines for Pharmacovigilance Inspections
PHARMACY BOARD OF SIERRA LEONE Guidelines for Pharmacovigilance Inspections Guideline No. : PBSL/PVGCT/GDL/QPPV/04-2017 Effective Date. :27 th March, 2017 Version No. : 01 1 TABLE OF CONTENT TABLE OF CONTENT
More informationInformation on the Member States requirement for the nomination of a pharmacovigilane (PhV) contact person at national level
19 July 2017 EMA/INS/PhV/445316/2017 Committees and Inspections Information on the Member s requirement for the nomination of a pharmacovigilane (PhV) contact person at national level Based on Pharmacovigilance
More informationGuide for Recall of Medicinal Products for Human and Veterinary Use
Guide for Recall of Medicinal Products for Human and Veterinary Use SUR-G0019-3 22 NOVEMBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes
More informationGuide for Distributors of Medical Devices
Guide for Distributors of Medical Devices IA-G0004-1 8 FEBRUARY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 SCOPE 3
More informationMHRA GDP Symposium. Novotel London West, London 8 & 10 December #GMDPevents
MHRA GDP Symposium Novotel London West, London 8 & 10 December 2015 Complex Business Models - Outsourced Activities Presented by: Jacqueline Masayi, GDP Inspector Background Increased complexities of the
More informationCode of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products
Code of Practice for Holder of Certificate of Registration as an Importer and Exporter of Pharmaceutical Products March 2014 Table of Content INTRODUCTION 3 Section 1: GENERAL RESPONSIBILITIES OF HOLDER
More informationBSWH Technician Continuing Education 2016 Part 2: Pharmacy Law - Controlled Substance Security & Drug Supply Chain Security Act (DSCSA) Contact
BSWH Technician Continuing Education 2016 Part 2: Pharmacy Law - Controlled Substance Security & Drug Supply Chain Security Act (DSCSA) Contact Hours: 1.5 Objectives List some strategies regarding safe
More informationCommission Guidelines on Good Distribution Practice of Medicinal Products for Human Use
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Public Health and Risk Assessment Pharmaceuticals Brussels, SANCO/C8/AM/an D(2010) 380358 Commission Guidelines on Good Distribution Practice
More informationManufacturers serialisation challenges with FMD & DR implementation
Manufacturers serialisation challenges with FMD & DR implementation Mike Rose Vice President, Supply Chain Visibility, Johnson & Johnson Supply Chain Chairman of EFPIA s Supply Chain WG & FMD Implementation
More informationRomania. Raluca Vasilescu Cabinet M Oproiu. Pharmaceutical Trademarks 2015/2016. A Global Guide
Romania Raluca Vasilescu Cabinet M Oproiu Pharmaceutical Trademarks 2015/2016 A Global Guide Romania Cabinet M Oproiu Author Raluca Vasilescu Selection, clearance and registration In Romania, pharmaceutical
More informationBrexit Guidance for Stakeholders Human and veterinary medicines
Brexit Guidance for Stakeholders Human and veterinary medicines DATE: 03 JANUARY 2018 V.2 This guide does not purport to be an interpretation of law and/or regulations. The content provided is subject
More informationMINISTRY OF HEALTH ORDINANCE
MINISTRY OF HEALTH 1800 Pursuant to Article 114, paragraph 2, Article 120, paragraph 3 and Article 127 of the Medicinal Products Act (Official Gazette 76/2013), the Minister of Health hereby issues the
More informationEU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update
EU IDMP Taskforce Falsified Medicines Directive and European Medicines Verification System Update 19 th February 2016 EMA London Falsified Medicines February 9 th 2016 Delegated Regulation (EU) 2016/161
More informationEvaluation of Counterfeit Cases Impact of FMD & GDPs. Lorraine Nolan Healthcare Products Distribution Manager
Evaluation of Counterfeit Cases Impact of FMD & GDPs Wholesale Distribution Information Day, 28th September 2012 Lorraine Nolan Healthcare Products Distribution Manager Slide 1 Contents 1. Review of UK
More informationPharmaceutical Trademarks
Published by Pharmaceutical Trademarks 2012 Hungary Contributing firm Third Edition Hungary Contributing firm Author Georgina Busku Selection, clearance and registration The following trademarks may enjoy
More informationImplementation of EU Falsified Medicines Directive
Implementation of EU Falsified Medicines Directive Gerald W Heddell Director, Inspection, Enforcement & Standards Division 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Sanco.ddg1.d.6(2012)1117276 DELEGATED ACT ON THE CRITERIA TO BE
More informationVerification processes in the supply chain. Workshop for MAHs, Helsinki, 18 Sep 2018 Teijo Yrjönen, FiMVO
Verification processes in the supply chain Workshop for MAHs, Helsinki, 18 Sep 2018 Teijo Yrjönen, FiMVO Legislative background Directive 2011/62/EU (Falsified Medicines Directive) Commission Delegated
More informationData Collection Tools Functions, Indicators & Sub-Indicators
Data Collection Tools 27- Functions, Indicators & A. National regulatory system Indicator RS1: Legal framework for establishment of a regulatory system, mandate and enforcement power for each function
More informationImpact of the transposition of the European Clinical Trials Directive. CEMO, Paris 17 November 2004
Impact of the transposition of the European Clinical Trials Directive CEMO, Paris 17 November 2004 Dr Martine Dehlinger-Kremer VP Regulatory Affairs International Agenda Overview of key areas of Directive
More informationRegulatory Requirements & Recent Changes, including expectations for APIs & IMPs
Regulatory Requirements & Recent Changes, including expectations for APIs & IMPs Neil Raw - GMP Inspector Richard Andrews - Operations Manager 11 th November 2008 Programme: Regulatory Requirements Neil
More informationDRUGS RULES, 1976 DRUGS (IMPORT & EXPORT) RULES, 1976
DRUGS RULES, 1976 DRUGS (IMPORT & EXPORT) RULES, 1976 DRUGS (IMPORT & EXPORT) RULES, 1976 S R O. 890 (I)/76. In exercise of the powers conferred by Section 43 of the Drugs Act, 1976 (XXX! of 1976), the
More informationMedical Devices. LATVIA LAWIN Klavins & Slaidins
Medical Devices LATVIA LAWIN Klavins & Slaidins CONTACT INFORMATION Sarmis Spilbergs LAWIN Klavins & Slaidins Elizabetes 15, Riga, LV 1010, Latvia +371 67814848 sarmis.spilbergs@lawin.lv www.lawin.com
More informationQUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION
PHARMACEUTICAL INSPECTION CO-OPERATION SCHEME PS/W 1/2011 2 Annexes 22 July 2011 QUESTIONNAIRE FOR COMPETENT AUTHORITIES TO BE USED FOR ASSESSMENT, REASSESSMENT AND SELF- EVALUATION PIC/S 2011 Reproduction
More informationEuropean Union (EU) Falsified Medicines Directive
European Union (EU) Falsified Medicines Directive Mr. Mike Rose, Vice President, Supply Chain Visibility Johnson & Johnson 18 October 2017 GS1 2017 The Promise of Serialization EU Falsified Medicines Directive
More informationTaking a Leap Toward Global Supply Chain Efficiency - Part II
Taking a Leap Toward Global Supply Chain Efficiency - Part II 2 Supply Chain Brochure - Part II INTRODUCTION Pharmaceutical manufacturers face a number of challenges in the production and delivery of medicinal
More informationNew GMPs for Active Substances & Excipients. Presented by Eoin Hanley 4 July, 2016
New GMPs for Active Substances & Excipients Presented by Eoin Hanley 4 July, 2016 What we will cover in this session The changing landscape EC Guideline on principles of GDP of active substances Formalised
More informationEUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL
EUROPEAN COMMISSION HEALTH AND FOOD SAFETY DIRECTORATE-GENERAL Health systems, medical products and innovation Medicines: policy, authorisation and monitoring PHARM 723 PHARMACEUTICAL COMMITTEE 18 October
More informationMINISTRY OF HEALTH ORDINANCE
MINISTRY OF HEALTH 1799 Pursuant to Article 73, paragraph 2, Article 74, paragraph 2 and Article 89, paragraph 2 of the Medicinal Products Act (Official Gazette 76/2013), the Minister of Health hereby
More informationEU Falsified Medicines Directive. Gareth Jones
EU Falsified Medicines Directive Gareth Jones Why is it important to NPA Members? Will require new processes within community pharmacy from Feb 2019 (barcode scan and tamper check) Requires new IT systems
More informationInspection of API Manufacturers & Update on Registration Process
Inspection of API Manufacturers & Update on Registration Process Catherine Neary, GMP Inspector GMP Conference 7 February 2017 Dublin Presentation Contents HPRA Inspection Programme for API Manufacturers
More informationQualified Persons in the Pharmaceutical Industry. Code of Practice. March 2008
Qualified Persons in the Pharmaceutical Industry Code of Practice March 2008 Updated October 2009 Code of Practice for Qualified Persons 1. INTRODUCTION... 1 2. REGULATORY BASIS FOR THE QUALIFIED PERSON...
More informationPN 1880 Consignment of Excisable Products from EU Member States for Commercial Purposes
PN 1880 Consignment of Excisable Products from EU Member States for Commercial Purposes 1. Who Should Read This Leaflet? Persons, other than authorised warehousekeepers, who intend to acquire excisable
More informationFOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS
FOOD AND DRUGS AUTHORITY GUIDELINES FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS Document No. : FDA/SMC/SMD/GL-PVI/2013/02 Date of First Adoption : 1 st February, 2013 Date of Issue : 1 st March, 2013
More informationOfficial Journal of the European Union. (Non-legislative acts) REGULATIONS
9.2.2016 L 32/1 II (Non-legislative acts) REGULATIONS COMMISSION DELEGATED REGULATION (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83/EC of the European Parliament and of the Council by
More informationRegulatory Compliance Inspections at MAH Offices: Implications for Manufacturers
Regulatory Compliance Inspections at MAH Offices: Implications for Manufacturers Kevin O Donnell, Ph.D. Market Compliance Manager GMP & Market Compliance Info Day September 2012 Slide 1 What are Regulatory
More informationGuide to Fees for Veterinary Products
Guide to Fees for Veterinary Products FIN-G0003-16 2 JANUARY 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS ABBREVIATIONS
More informationHealth Canada Mutual Recognition Agreement (MRA) Programme
Health Canada Mutual Recognition Agreement (MRA) Programme Presentation to Association of Food and Drug Officials (AFDO) Kimby Barton, Health Canada June 9, 2018 Overview Regulatory Operations and Regions
More informationCOMPILATION OF COMMUNITY PROCEDURES ON INSPECTIONS AND EXCHANGE OF INFORMATION
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, implementation and legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations European Medicines Agency
More informationRussian Federation. Chapter 12. By Julianna Tabastajewa and Svetlana Rudevich
Chapter 12 Russian Federation By Julianna Tabastajewa and Svetlana Rudevich Legal System The Russian Federation is a federal state consisting of a total of 83 republics, regions, federal cities, autonomous
More informationAPI EUROPEAN GMP REQUIREMENTS. Alessio Ferrari
API EUROPEAN GMP REQUIREMENTS Alessio Ferrari SUMMARY GUIDELINES IMPLICATIONS FOR THE INDUSTRY ARTICLE 46 (F) OF DIRECTIVE 2001/83/EC PART I EU GMP Chapter 5 OFFICIAL MEASURES TO PROTECT. PROCEDURE TO
More informationRegulatory Update. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin
Regulatory Update Greg McGurk, GMP Manager (acting) GMP Conference 7 February 2017 Dublin GMP Update Chapter 3 - Premises and Equipment (into operation since 1 March 2015) Chapter 5 - Production (into
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationMedical Devices. LITHUANIA LAWIN Lideika, Petrauskas, Valiunas ir partneriai
Medical Devices LITHUANIA LAWIN Lideika, Petrauskas, Valiunas ir partneriai CONTACT INFORMATION Ruta Pumputiene LAWIN Lideika, Petrauskas, Valiunas ir partneriai Jogailos str. 9 / 1, LT-01116 Vilnius,
More informationEuropean Medicines Agency Inspections
European Medicines Agency Inspections London, 14 July 2008 Doc. Ref. EMEA/INS/GMP/361819/2008 COMMUNITY PROJECT ON THE PRACTICAL IMPLEMENTATION OF THE NEW OBLIGATIONS FOR MANUFACTURING AUTHORISATION HOLDERS
More informationQS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain
QS, GDP (+GMP?) Maintaining the Integrity of The Supply Chain Presented by: Karen Ginsbury For IFF 01 March, 2017 Pharma Supply Chain Manufacturer Wholesaler Raw Material Supply Production Transport Warehouse
More informationCMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Procedures
October 2017 CMDh/004/2005/Rev.15 CMDh Best Practice Guide on the processing of renewals in the Mutual Recognition and Decentralised Table of contents (optional) 1. Introduction... 2 2. Legal framework...
More informationEMEA POST-AUTHORISATION GUIDANCE ON PARALLEL DISTRIBUTION
European Medicines Agency Post-authorisation Evaluation of Medicines for Human Use London, 19 July 2006 EMEA/Ho/2368/Rev 4 EMEA POST-AUTHORISATION GUIDANCE ON PARALLEL DISTRIBUTION RELEASE FOR CONSULTATION
More informationDISTRIBUTION AND SUPPLY OF PLASMA DERIVED FRACTIONATED BLOOD PRODUCTS AND RECOMBINANT PRODUCTS IN NEW ZEALAND
REASON FOR CHANGE: Wholesaler s licences are now issued by the Ministry of Health rather than Medsafe; clarify the approval process for the supply of products only to authorised facilities and healthcare
More informationVETERINARY AND PHYTOSANITARY MATTERS
27.10.2017 - EEA AGREEMENT- ANNEX I p. 1 { 1 } ANNEX I VETERINARY AND PHYTOSANITARY MATTERS TABLE OF CONTENTS I. Veterinary Issues II. Feedingstuffs III. Phytosanitary Matters List provided for in Article
More informationProject responsibilities
Project responsibilities Tallinn November 24th, 2017 Our Mission Falsified / counterfeit medicines are a serious risk for the citizens all around the world New legislation published on the 9th February
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL GUIDELINE FOR A LICENCE TO MANUFACTURE, IMPORT, EXPORT OR DISTRIBUTE MEDICAL DEVICES & IVDs This guideline is intended to provide recommendations to applicants wishing to submit
More informationNew Pharmacovigilance legislation. Post-authorisation safety studies. ENCePP Plenary meeting. 3 May 2012
New Pharmacovigilance legislation Post-authorisation safety studies ENCePP Plenary meeting 3 May 2012 Presented by: Annalisa Rubino, PhV and Risk Management, EMA An agency of the European Union Why? Public
More informationGuidelines relating to good distribution practice for distributors of medical devices.
Guidelines relating to good distribution practice for distributors of medical devices. TABLE OF CONTENTS Introduction... 2 CHAPITRE 1 - Quality assurance system... 2 CHAPITRE 2 - Staff... 2 CHAPITRE 3
More informationImplementation of the safety features in medicinal products for human use
Circular published on the INFARMED I.P website in 4 th Sept.2017 Translation of the responsibility of APIFARMA (not official) Information Circular N. º 108/CD/100.20.200 Date: 01/09/1017 Subject: For:
More informationURGENT SAFETY RESTRICTION MEMBER STATE STANDARD OPERATING PROCEDURE
Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human URGENT SAFETY RESTRICTION MEMBER STATE STANDARD OPERATING PROCEDURE June 2000 Revision 3, December 2005 This document was
More informationRegulatory Update. Paul Sexton. QP Forum
Regulatory Update Paul Sexton QP Forum 16 th April, 2015 Content Updates on GMP Guidance Updates on EU Legislation Draft Ph Eur monograph on WFI including RO 2 Chapter 5 - Production Paragraphs 27 to 30
More informationSupervision of manufacturers: What is expected of National Competent Authorities?
Supervision of manufacturers: What is expected of National Competent Authorities? Fergus Sweeney, PhD, European Medicines Agency Head, Compliance and Inspections EU 28: Science, Medicines, Health Dubrovnik,
More informationModule VIII- Post-authorisation safety studies
Good Vigilance Practice Module VIII- Post-authorisation safety studies 4th Stakeholder Forum Xavier Kurz An agency of the European Union Post-authorisation safety study Any study relating to an authorised
More informationJournal of Chemical and Pharmaceutical Research
Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 0975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 2011, 3(6):88-98 Conduct of Inspections for Pharmaceutical Manufactures
More informationFalsified Medicines Directive: Irish Medicines Verification Organisation (IMVO) update for HPRA GMP Conference LEONIE CLARKE - 7 TH FEBRUARY 2017
Falsified Medicines Directive: Irish Medicines Verification Organisation (IMVO) update for HPRA GMP Conference LEONIE CLARKE - 7 TH FEBRUARY 2017 Safety Features Falsified Medicines Directive(2011/62/EU)
More informationB COUNCIL REGULATION (EC) No 1412/2006 of 25 September 2006 concerning certain restrictive measures in respect of Lebanon (OJ L 267, , p.
2006R1412 EN 01.07.2013 003.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B COUNCIL REGULATION (EC) No 1412/2006 of 25 September
More informationFMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE
Falsified Medicines Directive FMD error and alert messages guidance notes To accompany FMD scanning and alert messages chart (v7) December 2018 UPDATED GUIDANCE These guidance notes accompany the FMD error
More informationPHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR RECALL OF MEDICINES AND HEALTH PRODUCTS IN MALAWI
PHARMACY, MEDICINES & POISONS BOARD GUIDELINES FOR RECALL OF MEDICINES AND HEALTH PRODUCTS IN MALAWI Draft September 2015 1. INTRODUCTION The Malawi Pharmacy Medicines and Poisons Board (PMPB) was established
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE WITH PHARMACOVIGILANCE REGULATORY OBLIGATIONS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POSITION PAPER ON COMPLIANCE
More informationImplementation of the safety features in medicinal products for human use
Translation of the responsibility of APIFARMA (not official) Information Circular N.º XXX/CD/cód. class. Date: DD/MM/YYYY Subject: For: Implementation of the safety features in medicinal products for human
More informationWorking Party on Control of Medicines and Inspections. Final Version of Annex 16 to the EU Guide to Good Manufacturing Practice
Version 8 (final) EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market, regulatory environment, industries under vertical legislation Pharmaceuticals and cosmetics Brussels, July 2001 Working
More information